Kairos Pharma Ltd. will present groundbreaking research on its experimental cancer treatment KROS 101 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The poster presentation, scheduled for June 2 at McCormick Place, will detail the effects of KROS 101 on T effector cells, T regulatory cells, and intratumoral CD8 T cell cytotoxicity.
The research focuses on KROS 101, a small molecule GITR ligand agonist, which represents a potential advancement in cancer therapeutic approaches. By examining the compound's impact on various immune cell mechanisms, Kairos Pharma seeks to contribute to the understanding of optimizing cancer treatment strategies.
Company CEO John Yu, M.D., emphasized the significance of sharing these findings, highlighting the potential for advancing scientific discussions around innovative cancer therapies. The presentation provides an opportunity for researchers and medical professionals to gain insights into potential new approaches for addressing cancer's complex immune interactions.
This research aligns with Kairos Pharma's broader mission of utilizing structural biology to overcome drug resistance and immune suppression in cancer treatment. The company's ongoing efforts, including clinical trials for ENV105 targeting CD105, demonstrate a commitment to developing novel therapeutic interventions for challenging cancer types.
